Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.81 USD | +0.40% | +9.49% | -3.40% |
May. 03 | GSK plc : Back on track | |
May. 03 | Wall Street: optimism ahead of NFP, rates ease | CF |
Financials (USD)
Sales 2024 * | 60.27B | Sales 2025 * | 62.55B | Capitalization | 157B |
---|---|---|---|---|---|
Net income 2024 * | 7.18B | Net income 2025 * | 10.17B | EV / Sales 2024 * | 3.51 x |
Net Debt 2024 * | 53.77B | Net Debt 2025 * | 42.59B | EV / Sales 2025 * | 3.2 x |
P/E ratio 2024 * |
19.8
x | P/E ratio 2025 * |
14
x | Employees | 88,000 |
Yield 2024 * |
6.09% | Yield 2025 * |
6.19% | Free-Float | 59.09% |
Latest transcript on Pfizer, Inc.
1 day | +0.43% | ||
1 week | +9.49% | ||
Current month | +8.55% | ||
1 month | +2.17% | ||
3 months | +3.27% | ||
6 months | -11.04% | ||
Current year | -3.40% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
14.74% | 215 M€ | +10.80% | - | |
9.37% | 18 M€ | +3.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 27.81 | +0.40% | 60,568,852 |
24-05-02 | 27.7 | +1.91% | 69,649,012 |
24-05-01 | 27.18 | +6.09% | 97,521,564 |
24-04-30 | 25.62 | -0.08% | 38,017,739 |
24-04-29 | 25.64 | +0.94% | 41,674,405 |
Delayed Quote Nyse, May 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 157B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- PFE Stock